Most Recent

• Preclinical work on INS-3001 efficacy in renal fibrosis published
• Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
• Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
• Preclinical work on calcium oxalate inhibitors for renal indications published
• Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications